Idiopathic pulmonary fibrosis: treatment update

Adv Ther. 2011 Nov;28(11):986-99. doi: 10.1007/s12325-011-0066-5.

Abstract

Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic interstitial pneumonias. Despite multiple recent clinical trials, there is no strong evidence supporting a survival advantage for any agent in the management of patients with IPF. The limited effectiveness of current treatment regimes has led to a search for novel therapies including antifibrotic strategies. This article reviews the evidence supporting the treatments currently used in the management of IPF.

Publication types

  • Review

MeSH terms

  • Anti-Inflammatory Agents / therapeutic use
  • Anticoagulants / therapeutic use
  • Antioxidants / therapeutic use
  • Clinical Trials as Topic
  • Combined Modality Therapy / methods*
  • Combined Modality Therapy / trends
  • Disease Progression
  • Endothelin Receptor Antagonists
  • Humans
  • Idiopathic Pulmonary Fibrosis* / physiopathology
  • Idiopathic Pulmonary Fibrosis* / therapy
  • Immunosuppressive Agents / therapeutic use
  • Lung Transplantation
  • Medication Therapy Management / trends*
  • Outcome Assessment, Health Care
  • Oxygen Inhalation Therapy / methods*
  • Palliative Care
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Anti-Inflammatory Agents
  • Anticoagulants
  • Antioxidants
  • Endothelin Receptor Antagonists
  • Immunosuppressive Agents
  • Tumor Necrosis Factor-alpha